Sign up
Pharma Capital

All WideCells divisions to start generating revenues after UK regulator approval

João Andrade, chief executive of WideCells Group PLC (LON:WDC), tells Proactive's Andrew Scott they've taken a significant step today towards becoming an end-to-end stem cell service company.

The group's been granted a licence by the UK's Human Tissue Authority, which allows them to import, export, process, store and distribute for treatment umbilical cord blood and tissue.

What in practice this official sanction does is allow them, under its brand name BabyCells, to offer umbilical cord blood and tissue storage services to clients in the UK and Europe.


View full WDC profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.